Beyond Classical Reactivity Patterns: Hydroformylation of Vinyl and Allyl Arenes to Valuable β- and γ-Aldehyde Intermediates Using Supramolecular Catalysis
作者:Paweł Dydio、Remko J. Detz、Bas de Bruin、Joost N. H. Reek
DOI:10.1021/ja503033q
日期:2014.6.11
regioselective hydroformylation of vinyl and allyl arenes bearing an anionic group. In principle, the binding site of the ligand is used to preorganize a substrate molecule through noncovalent interactions with its anionic group to promote otherwise unfavorable reaction pathways. We demonstrate that this strategy allows for unprecedented reversal of selectivity to form otherwise disfavored β-aldehyde products
Study on the ArI-catalyzed intramolecular <i>oxy</i>-cyclization of 2-alkenylbenzamides to benzoiminolactones
作者:Huixia Liu、Xiaojun Deng、Xie Huang、Nan Ji、Wei He
DOI:10.1039/d0ob00612b
日期:——
A metal-free synthetic method toward the preparation of benzoiminolactones through oxy-cyclization of 2-alkenylbenzamides mediated by a catalyst/oxidant (ArI/mCPBA) system was developed.
[EN] CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS<br/>[FR] CERTAINES ENTITÉS CHIMIQUES, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
申请人:INTELLIKINE INC
公开号:WO2011008302A1
公开(公告)日:2011-01-20
Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PO kinase activity are described herein.
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
申请人:Ren Pingda
公开号:US20090312319A1
公开(公告)日:2009-12-17
Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS
申请人:Ren Pingda
公开号:US20110046165A1
公开(公告)日:2011-02-24
Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.